CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,468,126 | +2797.7% | 1,037,433 | +2028.1% | 0.02% | +1700.0% |
| Q2 2023 | $533,813 | +507.5% | 48,750 | +383.8% | 0.00% | – |
| Q1 2023 | $87,871 | -43.3% | 10,077 | -76.3% | 0.00% | – |
| Q3 2021 | $155,000 | -16.2% | 42,448 | 0.0% | 0.00% | – |
| Q2 2021 | $185,000 | -42.2% | 42,448 | -39.7% | 0.00% | – |
| Q1 2021 | $320,000 | -23.8% | 70,442 | -3.8% | 0.00% | – |
| Q4 2020 | $420,000 | +14.8% | 73,215 | +44.8% | 0.00% | – |
| Q3 2020 | $366,000 | +44.1% | 50,554 | -30.6% | 0.00% | – |
| Q2 2020 | $254,000 | +17.6% | 72,812 | -50.0% | 0.00% | – |
| Q1 2020 | $216,000 | +43.0% | 145,624 | +89.2% | 0.00% | – |
| Q4 2019 | $151,000 | -61.7% | 76,978 | 0.0% | 0.00% | -100.0% |
| Q3 2019 | $394,000 | +4277.8% | 76,978 | +5923.3% | 0.00% | – |
| Q2 2019 | $9,000 | -47.1% | 1,278 | 0.0% | 0.00% | – |
| Q1 2019 | $17,000 | +70.0% | 1,278 | 0.0% | 0.00% | – |
| Q4 2018 | $10,000 | -41.2% | 1,278 | -16.0% | 0.00% | – |
| Q3 2018 | $17,000 | -5.6% | 1,522 | +15.1% | 0.00% | – |
| Q2 2018 | $18,000 | – | 1,322 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |